Clinical Trials | September 29, 2021
Morpen Labs carves out diagnostics business to unlock value
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
Since its inception, over three million users have used MFine services with the platform clocking over three lakh monthly transactions
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
A high-value proposition recyclable film packed with industry-leading barrier and metal bond performance, sustainability quotient and U.S. FDA compliant
Remote screening of diabetic retinopathy can help in early detection, even before there are any noticeable vision changes
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
It is a recombinant nanoparticle protein-based vaccine
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
Subscribe To Our Newsletter & Stay Updated
